GH · Guardant Health, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · GH

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$982.02M	$739.02M	$563.95M	$449.54M	$373.65M	$286.73M
Cost of Revenue	$289.80M	-	-	-	-	-
Gross Profit	$692.22M	-	-	-	-	-
R&D	$364.19M	$347.75M	$367.19M	$373.81M	$263.22M	$149.86M
SG&A	$211.41M	$180.12M	$155.80M	$163.96M	$206.64M	$192.77M
Total Operating Expenses	$1.42B	$1.18B	$1.13B	$993.92M	$784.65M	$541.68M
D&A	$39.74M	$42.39M	$42.88M	$35.96M	$22.27M	$16.07M
Operating Income	($437.25M)	($443.59M)	($564.73M)	($544.38M)	($411.00M)	($254.95M)
Interest Expense	$2.58M	$2.58M	$2.58M	$2.58M	$2.58M	$4.77M
Income Tax	($1.26M)	$1.28M	$685.0K	$1.14M	$300.0K	$379.0K
Net Income	($416.28M)	($436.37M)	($384.77M)	($654.59M)	($405.67M)	($253.78M)
EPS - Basic	($3.32)	($3.56)	($4.28)	($6.41)	($2.60)	-
EPS - Diluted	($3.32)	($3.56)	($4.28)	($6.41)	($2.60)	-

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$378.20M	$525.54M	$1.13B	$141.65M	$492.20M	$832.98M
Accounts Receivable	$137.85M	$110.25M	$88.78M	$97.26M	$97.65M	$53.30M
Inventory	$85.88M	$71.08M	$61.95M	$51.60M	$30.67M	$22.72M
Accounts Payable	$54.44M	$38.55M	$51.74M	$68.91M	$17.58M	$7.34M
Current Assets	$1.47B	$1.06B	$1.35B	$1.19B	$1.11B	$1.89B
Total Assets	$2.01B	$1.49B	$1.79B	$1.61B	$2.20B	$2.27B
Current Liabilities	$302.73M	$225.58M	$205.92M	$193.22M	$194.69M	$66.81M
Long-term Debt	$1.50B	-	-	-	-	-
Total Liabilities	$2.11B	$1.63B	$1.63B	$1.55B	$1.56B	$916.19M
Stockholders' Equity	($99.31M)	($139.65M)	$158.68M	$60.18M	$645.00M	$1.30B
Retained Earnings	($2.99B)	($2.58B)	($2.14B)	($1.66B)	($1.01B)	($606.59M)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	($184.76M)	($239.86M)	($324.98M)	($309.46M)	($209.02M)	($103.93M)
Investing Cash Flow	($627.20M)	($261.31M)	$840.25M	$149.82M	($63.16M)	($617.09M)
Financing Cash Flow	$671.13M	($996.0K)	$477.38M	($189.09M)	($66.82M)	$1.41B
CapEx	$48.31M	$35.09M	$20.49M	$77.46M	$75.03M	$36.17M
Free Cash Flow	($233.07M)	($274.94M)	($345.46M)	($386.92M)	($284.05M)	($140.10M)

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	70.5%	-	-	-	-	-
Operating margin	-44.5%	-60.0%	-100.1%	-121.1%	-110.0%	-88.9%
EBITDA margin	-40.5%	-54.3%	-92.5%	-113.1%	-104.0%	-83.3%
Net margin	-42.4%	-59.0%	-68.2%	-145.6%	-108.6%	-88.5%
Free cash flow margin	-23.7%	-37.2%	-61.3%	-86.1%	-76.0%	-48.9%
FCF / Net income	0.56	0.63	0.90	0.59	0.70	0.55
R&D / Revenue	37.1%	47.1%	65.1%	83.2%	70.4%	52.3%
SG&A / Revenue	21.5%	24.4%	27.6%	36.5%	55.3%	67.2%
Effective tax rate	-	-	-	-	-	-
Return on assets	-20.7%	-29.4%	-21.5%	-40.7%	-18.4%	-11.2%
Return on equity	419.2%	312.5%	-242.5%	-1087.7%	-62.9%	-19.5%
Return on invested capital	-24.6%	-	-	-	-	-
Liquidity
Current ratio	4.84	4.68	6.54	6.17	5.72	28.27
Quick ratio	4.56	4.36	6.24	5.90	5.57	27.93
Cash ratio	1.25	2.33	5.50	0.73	2.53	12.47
Leverage
Debt / Equity	-15.14	-	-	-	-	-
Debt / Assets	0.75	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-169.4x	-171.9x	-219.1x	-211.2x	-159.5x	-53.5x
Equity multiplier	-20.28	-10.64	11.26	26.75	3.42	1.75
Liabilities / Assets	1.05	1.09	0.91	0.96	0.71	0.40
Efficiency
Asset turnover	0.49	0.50	0.32	0.28	0.17	0.13
Inventory turnover	3.37	-	-	-	-	-
Days sales outstanding	51d	54d	57d	79d	95d	68d
Days inventory outstanding	108d	-	-	-	-	-
Days payable outstanding	69d	-	-	-	-	-
Cash conversion cycle	91d	-	-	-	-	-
Valuation
P / E	-	-	-	-	-	-
P / B	-	-	19.1x	46.2x	15.1x	-
P / S	13.0x	5.1x	5.4x	6.2x	26.1x	-
EV / EBITDA	-	-	-	-	-	-
Growth
Revenue growth (YoY)	32.9%	31.0%	25.5%	20.3%	30.3%	33.8%
Revenue CAGR (3y)	29.8%	25.5%	25.3%	28.0%	-	-
Revenue CAGR (5y)	27.9%	28.1%	-	-	-	-
Gross profit growth (YoY)	-	-	-	-	-	-
Operating income growth (YoY)	1.4%	21.4%	-3.7%	-32.5%	-61.2%	-209.5%
Net income growth (YoY)	4.6%	-13.4%	41.2%	-61.4%	-59.8%	-235.5%
EPS growth (YoY)	6.7%	16.8%	33.2%	-146.5%	-	-
EPS CAGR (3y)	-	-	-	-	-	-
EPS CAGR (5y)	-	-	-	-	-	-
FCF growth (YoY)	15.2%	20.4%	10.7%	-36.2%	-102.7%	-112.8%
FCF CAGR (5y)	-	-	-	-	-	-
Book value growth (YoY)	28.9%	-	163.7%	-90.7%	-50.3%	62.6%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$982.02M total

Reportable Segment$982.02M · 100.0%

Product / service

$982.02M total

Oncology$683.60M · 69.6%

Biopharma Data$210.13M · 21.4%

Screening$79.73M · 8.1%

Licensing Other$8.56M · 0.9%

Geographic

$982.02M total

US$923.28M · 94.0%

Non Us$58.74M · 6.0%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-1.05

Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

3/9

Weak

✗Net income positive
✗Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✓Current ratio improved
✗No share dilution
-Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Services-Medical Laboratories

Company	Revenue (last FY)	Net margin	ROE
NTRA	$2.31B	-9.0%	-12.2%
LH	$13.95B	6.3%	10.2%
DGX	$11.04B	9.0%	13.8%
CSTL	$344.23M	-7.0%	-5.1%
BDSX	$88.50M	-39.8%	1430.6%

Comparing Guardant Health against the 5 most active filers in the same SIC group.